

Gene to GMP, Translating Concept into Cure

The first integrated platform combining proprietary enzymatic synthetic DNA with advanced therapy development and GMP manufacturing.

SYNTHETIC DNA

Our oDNA Platform

Truly synthetic oDNA— your gene of interest, enzymatically produced up to gram scale, free of biological contamination — is the superior starting material for every application in genetic medicine.

PLASMID DNA

- ✗ 2–3 months production
- ✗ Endotoxin contamination
- ✗ Antibiotic markers
- ✗ Scaling complexity

- ✓ **Ready in 2 weeks**
- ✓ **Endotoxin-free**
- ✓ **Cell-free**
- ✓ **Easy to scale**

KEY PLATFORM CAPABILITIES

Truly Synthetic
RUO & GMP grades,
no plasmid dependency

Application-Specific
oDNA & adapter formats built
to maximize functionality

2-Week Timelines
For RUO-grade delivery &
3–4 weeks for GMP-grade

US & EU Production
Two manufacturing sites for
global access & derisked supply

Optimized DNA (oDNA)



Optimization starts at the source.

Control the DNA. Control the downstream.
For complete details about how an integrated DNA
platform can accelerate your program, visit:

→ syngoi.com

MODALITIES

Multiple Advanced Therapy Modalities on One Platform



Synthetic DNA
Enzymatic
plasmid-free oDNA



Cell Therapies
CAR-T, stem cells,
autologous, allogeneic



Viral Vectors
AAV & LVV,
50–200L



mRNA & LNP
IVT, formulation



Non-Viral
Nanoparticles,
extracellular vesicles



Emerging
Novel vectors &
new technology

PARTNERING

Flexible engagement models

Collaborations designed for programs at any stage
and any support level required



On-Demand Production Platforms

- Plug-&-play Platform Optimized for Scale-up & Transfer (POSTmark) for LVV, AAV, & CAR-T
- Identical non-GMP & GMP systems
- In-house analytics accelerate development & scalability
- IND-ready in 9–12 months.



Client-Owned Execution

- Hybrid/Modular service offerings
- Transfer your process and methods into Artis' facility
- GMP-ready protocols executed by Artis
- Leverage capabilities across development, manufacturing, & regulatory readiness



Joint Innovation

- Co-development with deep scientific collaboration
- Tailored to reach your next program milestone
- Process & analytical development through scale-up
- CMC regulatory support & IND enablement

WHO WE ARE

Artis BioSolutions is a synthetic DNA and advanced therapy platform

We build the DNA that powers genetic medicine and translate it into clinical-grade therapies through integrated manufacturing.

The advanced therapy industry has relied on fragmented supply chains, legacy plasmid DNA, and disconnected vendors. Artis was built to replace that model — the first integrated platform combining proprietary enzymatic synthetic DNA production with advanced therapy development and GMP manufacturing, with operations in the US and EU.

WHY ARTIS

- **Next-generation starting material**
Synthetic DNA in. Bacteria & plasmids out.
- **One unified solution**
From DNA through clinical supply.
- **Dual-continent operations**
Boston, US + Bilbao, Spain.
- **No vendor handoffs**
No knowledge loss between stages.
- **Flexible partnership models**
Collaboration at any program stage.

AT A GLANCE

80,000+ sq ft

Total facility space

2 & 4 weeks

RUO & GMP DNA lead time

30+

Concurrent projects

9–12 months

Program start to IND-readiness

OUR FACILITIES

Two continents. One integrated platform.



ARTIS
BIOSOLUTIONS

Boston, US ADVANCED THERAPY HUB

- 44,000 sq ft purpose-built facility
- 8 cell processing suites (ISO 7)
- 1 viral vector suite (ISO 8)
- Modular Innovation & Development Labs
- In-house Bioanalytical & Microbiology QC
- Minutes from Boston clinical centers



syngoi
AN ARTIS BIOSOLUTIONS COMPANY

Bilbao, Spain SYNGOI · AN ARTIS COMPANY

- 37,000 sq ft production facility
- GMP-ready enzymatic synthetic DNA
- 4 cGMP processing suites
- 1 fill/finish suite & 8 preclinical/R&D labs
- Gram-scale DNA production capacity
- Technology Park of Zamudio, Basque Country

Let's build forward together.

Whether you're an early-stage innovator or an established biopharma, we function as a long-term partner.

inquiries@artisbiosolutions.com
artisbiosolutions.com · syngoi.com



SERVICES

An Integrated Platform from Starting Material to the Clinic

Fully integrated services with disciplined, end-to-end execution — from synthetic DNA through GMP manufacturing, all within a single quality framework.



Synthetic DNA Manufacturing

GMP-ready and RUO oDNA, enzymatically produced up to gram scale.



CMC Strategy & Regulatory

Lifecycle-oriented CMC and IND-enabling planning from day one.



Process & Formulation Development

Phase-appropriate, modality-specific PD with scalability built in.



Analytical Development & QC

AD and QC under a single unified team for clean methods transfer.



GMP Manufacturing & Fill/Finish

Modular cGMP suites and aseptic fill/finish for clinical supply.

De-risk. Accelerate. Scale.

One integrated team, one quality framework, continuous process understanding — from DNA to clinical supply.

→ inquiries@artisbiosolutions.com